Form 4: Prothena CDO Granted 190,000 Stock Options

Prothena's Chief Development Officer, Chad J. Swanson, was granted 190,000 stock options with an exercise price of $9.36, vesting over four years.

Summary

• Chad J. Swanson, Chief Development Officer of Prothena Corp Public Ltd Co (PRTA), was granted 190,000 stock options.
• The options have an exercise price of $9.36 per share.
• The transaction date for the grant was March 3, 2026.
• The options will vest as to 25% of the total number of shares on March 3, 2027.
• Following the initial vesting, 1/48th of the total shares will vest in successive, equal monthly installments on each monthly anniversary thereafter.
• The vesting is contingent upon Mr. Swanson's continued employment with Prothena.
• The expiration date for these stock options is March 3, 2036.
• Following this transaction, Mr. Swanson beneficially owns 190,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with shareholder value creation and aid in executive retention.

Positives

• The grant of stock options aligns the Chief Development Officer's financial interests with those of shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for retaining key executives and encouraging their continued commitment to the company's strategic objectives.

Risks

• The vesting of the stock options is subject to the Reporting Person's continued employment with the Issuer on each vesting date, meaning the options could be forfeited if employment ceases.

Future Outlook

The structured vesting schedule for the stock options indicates a long-term commitment from the Chief Development Officer, aligning his incentives with the company's future development and success over the next four years, contingent on continued employment.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the Chief Development Officer is a common and widely accepted practice in the biotechnology and pharmaceutical industries. This form of compensation is designed to attract, retain, and motivate top talent by linking their personal wealth directly to the company's stock performance and long-term strategic achievements.

Comparison to Industry Standards

• The four-year vesting schedule with a one-year cliff (25% after one year) followed by monthly vesting is a standard industry practice for executive equity grants, comparable to compensation structures seen at companies like Biogen Inc. or Eli Lilly and Company for similar roles.
• The exercise price being set at the grant date's market price is typical for incentive stock options, ensuring the executive benefits only if the stock price appreciates from the grant date.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also benefit from increased alignment of executive interests with long-term stock performance.
• Employees: Reinforces the company's commitment to executive retention and performance-based compensation.

Next Steps

• Continued employment of Chad J. Swanson with Prothena to ensure vesting of options.
• Future disclosures of any exercise or sale of these options by Mr. Swanson.

Key Dates

Keywords

Prothena, PRTA, Stock Options, Executive Compensation, Insider Transaction, Form 4, Chad J. Swanson, Chief Development Officer, Equity Grant